Novel enhanced delivery taxanes: an update

Area of Science:

• Oncology
• Pharmacology
• Nanotechnology

Background:

• Taxanes are crucial chemotherapeutic agents for solid tumors, including metastatic breast cancer.
• Conventional taxane formulations often require toxic solvents, leading to side effects.
• Enhanced-delivery taxanes (EDTs) were developed to improve taxane delivery and tolerability.

Purpose of the Study:

• To review the advancements in enhanced-delivery taxanes (EDTs) for cancer therapy.
• To highlight the mechanisms and benefits of second-generation EDTs.
• To discuss the potential of EDTs in improving taxane pharmacokinetics and patient outcomes.

Main Methods:

• Review of existing literature on taxanes and enhanced-delivery systems.
• Analysis of the mechanisms of action for first- and second-generation EDTs.
• Discussion of pharmacokinetic profiles and tumor-targeting strategies.

Main Results:

• First-generation EDT, nab-paclitaxel, uses albumin nanoparticles for tumor delivery.
• Second-generation EDTs, like Tocosol Paclitaxel and paclitaxel poliglumex, utilize advanced vehicles.
• EDTs leverage tumor characteristics like enhanced permeability and retention (EPR) for selective drug accumulation.
• EDTs demonstrate potential for improved bioavailability at the tumor site and reduced systemic toxicity.

Conclusions:

• EDTs offer a promising strategy to enhance the therapeutic index of taxanes.
• These advanced formulations minimize exposure to healthy tissues, improving tolerability.
• EDTs represent a significant advancement in targeted cancer chemotherapy delivery.